Clinical research
Retrophin, Inc. announced that the Phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration did not meet its primary endpoint and did not demonstrate a difference between treatment groups.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
Shares of Retrophin have plunged more than 24% in premarket trading after the San Diego-based company announced its Phase III treatment for pantothenate kinase-associated neurodegeneration did not stack up against placebo.
MyoKardia, Inc. announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy.
Over a 12-week course of treatment, Teva said fremanezumab provided patients with statistically significant reductions in monthly average number of migraine days. The results of the study were published in Lancet.
NuCana halted enrollment of patients in the Phase III ACELERATE trial on the advice of the study’s Independent Safety and Data Monitoring Committee.
The Phase III NEPTUNE trial assessed the combination treatment as a first-line treatment in an “all-comers population,” with the primary analysis population being patients with a high tumor mutational burden.
Forendo Pharma announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism.
AstraZeneca announced that its Phase III DAPA-HF clinical trial of Farxiga (dapagliflozin) met its primary endpoint in decreasing cardiovascular death or the worsening of heart failure compared to placebo.
“It’s important to recognize that this problem is there and this problem is persisting over the years,” Kanwal Raghav, author of the study and an oncologist at MD Anderson Cancer Center, told STAT.
PRESS RELEASES